Formulation of dacarbazine-loaded Cubosomes--part II: influence of process parameters.
The purpose of this study is to investigate the combined influence of process parameters (independent variables) such as homogenization speed (X(1)), duration (X(2)), and temperature (X(3)) during the preparation of dacarbazine-loaded cubosomes. Box-Behnken design was used to rationalize the influence of these three factors on two responses, namely particle size (Y(1)) and encapsulation efficiency (Y(2)). Independent and dependent variables were analyzed with multiple regressions to establish a full-model second-order polynomial equation. F value was calculated to confirm the omission of insignificant parameters or interactions of parameters from the analysis to derive a reduced-model polynomial equation to predict the Y(1) and Y(2) of dacarbazine-loaded cubosomes. Pareto charts were also obtained to show the effects of X(1), X(2), and X(3) on Y(1) and Y(2). For Y(1), there was a model validated for more accurate prediction of response parameter by performing checkpoint analysis. The optimization process and Pareto charts were obtained automatically and they predicted the levels of independent parameters X(1), X(2), and X(3) (0.889794, 0.11886, and 0.56201, respectively) and minimized Y(1). The optimal process parameters (homogenization's speed = approximately 24,000 rpm, duration = 5.5 min, and temperature = 76 degrees C) led to the production of cubosomes with 85.6 nm in size and 16.7% in encapsulation efficiency. The Box-Behnken design proved to be a useful tool in the preparation and optimization of dacarbazine-loaded cubosomes. For encapsulation efficiency (Y(2)), further studies are needed to enhance the result and improve the model for such water-soluble drug encapsulation in cubosomes.
Bei
Di
D
Division of Pharmaceutical Sciences, University of Missouri-Kansas City School of Pharmacy, Kansas City, Missouri 64110-2499, USA.
Marszalek
Jacob
J
Youan
Bi-Botti C
BB
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D003606:Dacarbazine / Q000008:administration & dosage / Q000737:chemistry*; D004339:Drug Compounding; D005079:Excipients; D046529:Microscopy, Electron, Transmission; D015233:Models, Statistical; D053758:Nanoparticles; D010316:Particle Size
D000970:Antineoplastic Agents; D005079:Excipients; D003606:Dacarbazine
Eur J Pharm Sci. 2006 Jan;27(1):44-53
16157479
AAPS PharmSciTech. 2008;9(4):1092-6
18850275
AAPS PharmSciTech. 2009;10(3):1032-9
19669896
Biol Pharm Bull. 2007 Feb;30(2):350-3
17268078
Int J Cosmet Sci. 2007 Oct;29(5):335-52
18489367
Colloids Surf B Biointerfaces. 2004 Apr 15;34(4):253-8
15261065
J Colloid Interface Sci. 2003 Apr 15;260(2):404-13
12686193
Langmuir. 2008 Mar 18;24(6):2573-9
18247638
Nano Lett. 2005 Aug;5(8):1615-9
16089498
Pharmacol Rev. 2001 Jun;53(2):283-318
11356986
Ann Oncol. 2006 Apr;17(4):563-70
16418308
AAPS PharmSciTech. 2007 Oct 19;8(4):E86
18181547
Langmuir. 2005 Mar 15;21(6):2569-77
15752054
Nature. 1968 Nov 2;220(5166):485-8
5686165
AAPS PharmSci. 2003 Nov 18;5(4):E30
15198518
Eur J Pharm Biopharm. 2006 Jun;63(2):128-33
16497495
Int J Pharm. 2007 Feb 1;329(1-2):150-7
16987623
Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):229-50
11311994
AAPS PharmSciTech. 2009;10(1):193-8
19238555
J Am Chem Soc. 2002 Oct 16;124(41):12255-60
12371867